Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors
Clinical trial NCT06349837 · RECRUITING
Trial details
- NCT number
- NCT06349837
- Sponsor
- Sichuan University
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-04-18
- Primary completion
- 2028-03-31
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.